AuthorCitation

Faculty Opinions recommendation of Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 17, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.726465378.793525471

Faculty Opinions recommendation of Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 17, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.726356653.793525469

Faculty Opinions recommendation of The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 17, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.726281749.793525470

Faculty Opinions recommendation of Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 17, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.726978664.793525467

Faculty Opinions recommendation of A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 17, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.726978662.793525466

Faculty Opinions recommendation of Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 17, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.725994198.793525468

Faculty Opinions recommendation of A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 17, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.725400916.793525465

Faculty Opinions recommendation of PARP-2 and PARP-3 are selectively activated by 5' phosphorylated DNA breaks through an allosteric regulatory mechanism shared with PARP-1.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 4, 2014 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.718449416.793501137

Faculty Opinions recommendation of Small-molecule activation of the TRAIL receptor DR5 in human cancer cells.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | March 15, 2013 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.717988213.793472490

Meng, Wei

Citations 19

Faculty Opinions recommendation of Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia.

Faculty Opinions recommendation of Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.

Faculty Opinions recommendation of The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.

Faculty Opinions recommendation of Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study.

Faculty Opinions recommendation of A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors.

Faculty Opinions recommendation of Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

Faculty Opinions recommendation of A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia.

Faculty Opinions recommendation of PARP-2 and PARP-3 are selectively activated by 5' phosphorylated DNA breaks through an allosteric regulatory mechanism shared with PARP-1.

Faculty Opinions recommendation of Small-molecule activation of the TRAIL receptor DR5 in human cancer cells.